Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Can the pioneer of mRNA vaccines outpace the king of cystic fibrosis treatments? Choosing between Moderna (NASDAQ:MRNA) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires weighing high-growth potential against established, profitable market dominance. Moderna seeks to prove its mRNA technology works across many diseases, while Vertex focuses on specialized medicines for serious conditions. Both companies are major players in the biotechnology space, but they offer vastly different financial profiles and risk levels for investors eyeing 2026. Choosing the right one depends on your personal appetite for volatility. Moderna sells mRNA-based medicines, primarily focusing on infectious disease vaccines like Spikevax and mNEXSPIKE for COVID-19. The company maintains a global manufacturing footprint and operates in the biotech stocks landscape. It frequently collaborates with partners like Merck (NYSE:MRK) on oncology candidates and recently partnered with Recordati to advance new therapeutics. Continue reading